ALLK

Allakos Inc

Add to Watchlist

Advanced Chart

0.000

-0.329(-99.970%)1D

Overview
Forecast
Valuation
Earnings

High

Open

VWAP

Vol

Mkt Cap

93.86M

Low

Amount

EV/EBITDA(TTM)

Total Shares

88.54M

-25.49M

EV/OCF(TTM)

P/S(TTM)

Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.190

-36.67%

-0.020

-90.48%

-0.020

-92.39%

Estimates Revision

Stock Price

Go Up

+1.26%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ALLK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLK is 0.40 USD with a low forecast of 0.40 USD and a high forecast of 0.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 0

Low

0.40

Averages

0.40

High

0.40

Current: 0

Low

0.40

Averages

0.40

High

0.40

JMP Securities

Jonathan Wolleben

Buy

Reiterates

2024-09-26

Reason

JMP Securities

Jonathan Wolleben

Price Target

2024-09-26

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Allakos Inc (ALLK.O) is -0.70, compared to its 5-year average forward P/E of -7.53. For a more detailed relative valuation and DCF analysis to assess Allakos Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.53

Current PE

-0.70

Overvalued PE

2.00

Undervalued PE

-17.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.15

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.77

Undervalued EV/EBITDA

-18.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00